Nkarta Inc (NKTX) - Net Assets
Based on the latest financial reports, Nkarta Inc (NKTX) has net assets worth $312.32 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($404.21 Million) and total liabilities ($91.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Nkarta Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $312.32 Million |
| % of Total Assets | 77.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | 24.45% |
| 10-Year Change | N/A |
| Growth Volatility | 35.68 |
Nkarta Inc - Net Assets Trend (2018–2025)
This chart illustrates how Nkarta Inc's net assets have evolved over time, based on quarterly financial data. Also explore NKTX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Nkarta Inc (2018–2025)
The table below shows the annual net assets of Nkarta Inc from 2018 to 2025. For live valuation and market cap data, see market value of Nkarta Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $312.32 Million | -23.45% |
| 2024-12-31 | $407.98 Million | +49.29% |
| 2023-12-31 | $273.29 Million | -26.58% |
| 2022-12-31 | $372.21 Million | +48.31% |
| 2021-12-31 | $250.97 Million | -21.87% |
| 2020-12-31 | $321.22 Million | +1360.55% |
| 2019-12-31 | $-25.48 Million | -372.25% |
| 2018-12-31 | $-5.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nkarta Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64272409300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $407.00K | 0.13% |
| Other Components | $960.22 Million | 307.44% |
| Total Equity | $312.32 Million | 100.00% |
Nkarta Inc Competitors by Market Cap
The table below lists competitors of Nkarta Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Akenerji Elektrik Uretim AS
IS:AKENR
|
$166.91 Million |
|
Flutter Entertainment PLC
LSE:FLTR
|
$166.92 Million |
|
Usun Technology Co Ltd
TWO:3498
|
$166.92 Million |
|
Mieco Chipboard Bhd
KLSE:5001
|
$166.96 Million |
|
Yapi Kredi Koray Gayrimenkul Yatirim Ortakligi AS
IS:KGYO
|
$166.79 Million |
|
Cristales
SN:CRISTALES
|
$166.77 Million |
|
Mosel Vitelic Inc
TW:2342
|
$166.75 Million |
|
Core Molding Technologies Inc
NYSE MKT:CMT
|
$166.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nkarta Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 407,976,000 to 312,325,000, a change of -95,651,000 (-23.4%).
- Net loss of 104,084,000 reduced equity.
- Other comprehensive income decreased equity by 267,000.
- Other factors increased equity by 8,700,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-104.08 Million | -33.33% |
| Other Comprehensive Income | $-267.00K | -0.09% |
| Other Changes | $8.70 Million | +2.79% |
| Total Change | $- | -23.45% |
Book Value vs Market Value Analysis
This analysis compares Nkarta Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.69x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.11 | $2.93 | x |
| 2019-12-31 | $-2.84 | $2.93 | x |
| 2020-12-31 | $10.10 | $2.93 | x |
| 2021-12-31 | $7.64 | $2.93 | x |
| 2022-12-31 | $8.53 | $2.93 | x |
| 2023-12-31 | $5.58 | $2.93 | x |
| 2024-12-31 | $6.01 | $2.93 | x |
| 2025-12-31 | $4.22 | $2.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nkarta Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-33.33%) is below the historical average (-24.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -4.19% | 0.68x | 0.00x | $265.10K |
| 2019 | 0.00% | -18265.66% | 0.00x | 0.00x | $-18.53 Million |
| 2020 | -28.44% | -23730129.87% | 0.00x | 1.05x | $-123.48 Million |
| 2021 | -33.45% | 0.00% | 0.00x | 1.09x | $-109.05 Million |
| 2022 | -32.09% | 0.00% | 0.00x | 1.27x | $-156.65 Million |
| 2023 | -43.00% | 0.00% | 0.00x | 1.39x | $-144.83 Million |
| 2024 | -26.67% | 0.00% | 0.00x | 1.23x | $-149.59 Million |
| 2025 | -33.33% | 0.00% | 0.00x | 1.29x | $-135.32 Million |
Industry Comparison
This section compares Nkarta Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nkarta Inc (NKTX) | $312.32 Million | 0.00% | 0.29x | $166.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more